Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.61 |
| ▸ | HTR2C | P28335 | 15/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248244 | 0.80 | CACNA1G (0.51) | HTR2AHTR2CSLC6A4DRD2DRD3 | |
| SCHEMBL4251622 | 0.80 | MEN1 (0.52) | HTR2AHTR2CSLC6A4DRD2DRD3 | |
| SCHEMBL3300566 | 0.79 | KMT2A (0.56) | HTR2AHTR2CSLC6A4DRD2 | |
| SCHEMBL4251617 | 0.79 | HTR2A (0.49) | HTR2AHTR2CSLC6A4DRD2DRD3 | |
| SCHEMBL2681699 | 0.78 | HTR2A (0.90) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL1077440 | 0.78 | HTR2A (0.88) | HTR2AHTR2CSLC6A4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2683212 | 0.78 | HTR2A (0.91) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL20328177 | 0.78 | HTR2A (0.44) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL4252495 | 0.77 | CACNA1G (0.53) | HTR2AHTR2CSLC6A4DRD2DRD3 | |
| SCHEMBL2683102 | 0.77 | HTR2A (0.80) | HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | HTR2A 522/4885HTR2C 1281/4885SLC6A4 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.